-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Carlsmed, Raises Price Target to $20

Benzinga·11/07/2025 15:49:03
Listen to the news
Truist Securities analyst Richard Newitter reiterates Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.